Final results of phase Ib of tarextumab (TRXT, OMP-59R5, anti-Notch2/3) in combination with etoposide and platinum (EP) in patients (pts) with untreated extensive-stage small-cell lung cancer (ED-SCLC)

Autor:	Robert M. Jotte, Lei Zhou, Lowell L. Hart, Alain C. Mita, Dawn Hill, Anne C. Chiang, David R. Spigel, W Larry Gluck, Jakob Dupont, Ann M. Kapoun, Shirish M. Gadgeel, Lu Xu, Stephen V. Liu, Maria Catherine Pietanza, Alexander I. Spira
Rok vydání:	2015
Předmět:	Cancer Research business.industry Notch signaling pathway Pharmacology respiratory tract diseases Oncology Cancer stem cell Cancer research Medicine In patient Tarextumab business Extensive-stage small cell lung cancer Etoposide medicine.drug
Zdroj:	Journal of Clinical Oncology. 33:7508-7508
ISSN:	1527-7755 0732-183X
Popis:	7508 Background: Notch signaling is implicated in cancer stem cell self-renewal and proliferation; thus being an appealing target in the treatment of SCLC. Tarextumab (TRXT), a fully human IgG2 ant...
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::594ad2469bde0c57b5a13406b4d9662d https://doi.org/10.1200/jco.2015.33.15_suppl.7508 Zobrazit plný text záznamu